For example, clinical trials of PD-1 inhibitors for squamous-cell lung cancer and ovarian cancer showed no correlation between clinical effect and PD-L1 expression on tumor tissues [57, 60, 64]. This evidence concerns the gene PDCD1 and neoplasm.